Concepts (69)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Esophageal Neoplasms | 3 | 2022 | 359 | 0.830 |
Why?
|
| Biomimetics | 1 | 2021 | 15 | 0.750 |
Why?
|
| Cisplatin | 1 | 2021 | 242 | 0.680 |
Why?
|
| Mesothelioma | 3 | 2024 | 54 | 0.630 |
Why?
|
| Lung Transplantation | 1 | 2022 | 316 | 0.600 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 550 | 0.590 |
Why?
|
| Peptide Fragments | 1 | 2021 | 748 | 0.570 |
Why?
|
| Neoplasm Staging | 5 | 2025 | 1213 | 0.460 |
Why?
|
| Lung Neoplasms | 4 | 2025 | 1580 | 0.450 |
Why?
|
| Adenocarcinoma | 3 | 2022 | 992 | 0.440 |
Why?
|
| Pleural Neoplasms | 2 | 2024 | 42 | 0.440 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 1870 | 0.440 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 1432 | 0.440 |
Why?
|
| Second-Look Surgery | 1 | 2010 | 4 | 0.360 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2010 | 7 | 0.360 |
Why?
|
| Hyperthermia, Induced | 1 | 2010 | 44 | 0.340 |
Why?
|
| Peritoneal Neoplasms | 1 | 2010 | 28 | 0.340 |
Why?
|
| Laparotomy | 1 | 2010 | 135 | 0.320 |
Why?
|
| Colorectal Neoplasms | 1 | 2010 | 560 | 0.230 |
Why?
|
| Pneumonectomy | 1 | 2025 | 128 | 0.220 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 1230 | 0.220 |
Why?
|
| Thoracic Surgery | 1 | 2025 | 157 | 0.210 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2021 | 15 | 0.190 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2021 | 70 | 0.190 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2025 | 333 | 0.190 |
Why?
|
| Drug Synergism | 1 | 2021 | 240 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2021 | 172 | 0.180 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 1062 | 0.160 |
Why?
|
| Melanoma | 1 | 2022 | 823 | 0.120 |
Why?
|
| Skin Neoplasms | 1 | 2022 | 794 | 0.120 |
Why?
|
| Apoptosis | 1 | 2021 | 1781 | 0.120 |
Why?
|
| Cell Proliferation | 1 | 2021 | 2307 | 0.110 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 1677 | 0.100 |
Why?
|
| Treatment Outcome | 2 | 2022 | 12116 | 0.100 |
Why?
|
| Organoplatinum Compounds | 1 | 2010 | 29 | 0.090 |
Why?
|
| Humans | 9 | 2025 | 123146 | 0.090 |
Why?
|
| Leucovorin | 1 | 2010 | 50 | 0.090 |
Why?
|
| Sample Size | 1 | 2010 | 84 | 0.090 |
Why?
|
| Fluorouracil | 1 | 2010 | 128 | 0.090 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 353 | 0.080 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 860 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2024 | 6027 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 2 | 2025 | 1259 | 0.060 |
Why?
|
| Neoplasm Metastasis | 1 | 2025 | 649 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2022 | 4705 | 0.050 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2022 | 56 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2022 | 278 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2010 | 3329 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2025 | 679 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 1 | 2022 | 321 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2022 | 313 | 0.040 |
Why?
|
| Time Factors | 1 | 2010 | 6205 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2022 | 467 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2024 | 1170 | 0.040 |
Why?
|
| Survival Rate | 1 | 2022 | 1993 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 1240 | 0.040 |
Why?
|
| Aged | 2 | 2024 | 19068 | 0.030 |
Why?
|
| Risk Factors | 1 | 2010 | 10011 | 0.030 |
Why?
|
| Prognosis | 1 | 2024 | 4505 | 0.030 |
Why?
|
| Middle Aged | 2 | 2024 | 25964 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2024 | 6372 | 0.030 |
Why?
|
| Quality of Life | 1 | 2022 | 1932 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2022 | 3083 | 0.020 |
Why?
|
| Young Adult | 1 | 2024 | 8864 | 0.020 |
Why?
|
| Male | 2 | 2024 | 60034 | 0.020 |
Why?
|
| Female | 2 | 2024 | 65443 | 0.020 |
Why?
|
| Adolescent | 1 | 2024 | 19093 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2022 | 16000 | 0.010 |
Why?
|
| Adult | 1 | 2024 | 29029 | 0.010 |
Why?
|